Inari Medical (NARI) Receives a Buy from Morgan Stanley

Morgan Stanley analyst Cecilia Furlong maintained a Buy rating on Inari Medical (NARIResearch Report) today and set a price target of $93.00. The company’s shares closed last Friday at $73.82.

According to TipRanks.com, Furlong is a 4-star analyst with an average return of 19.6% and a 45.2% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Bausch + Lomb Corporation, and Irhythm Technologies.

Currently, the analyst consensus on Inari Medical is a Strong Buy with an average price target of $99.00.

See Insiders’ Hot Stocks on TipRanks >>

Based on Inari Medical’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $86.75 million and GAAP net loss of $3.13 million. In comparison, last year the company earned revenue of $57.4 million and had a net profit of $7.47 million.

Based on the recent corporate insider activity of 94 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NARI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.

Read More on NARI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed